Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Firazyr
Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
